Stocks of Boston Scientific Corp. (NYSE:BSX) traded higher last session on Wall Street, down -0.12% to $73.17.
BSX stock price is now 8.19% away from the 50-day moving average and 26.41% away from the 200-day moving average. The market capitalization of the company currently stands at $107.55B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $65 to $80, Mizuho Upgraded its rating from Neutral to Buy for Boston Scientific Corp. (NYSE: BSX). On July 19, 2023, Robert W. Baird recently initiated its ‘Outperform’ rating on the stock quoting a target price of $59, while ‘CL King’ rates the stock as ‘Buy’
In other news, Sorenson John Bradley, EVP, Global Operations sold 16,351 shares of the company’s stock on Apr 01 ’24. The stock was sold for $1,133,069 at an average price of $69.30. Upon completion of the transaction, the EVP, Global Operations now directly owns 50,638 shares in the company, valued at $3.71 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 01 ’24, EVP, Human Resources Carruthers Wendy sold 6,983 shares of the business’s stock. A total of $477,777 was realized by selling the stock at an average price of $68.42. This leaves the insider owning 51,068 shares of the company worth $3.74 million. A total of 0.45% of the company’s stock is owned by insiders.
During the past 12 months, Boston Scientific Corp. has had a low of $48.35 and a high of $74.39. As of last week, the company has a debt-to-equity ratio of 0.49, a current ratio of 1.32, and a quick ratio of 0.82.
According to the Medical Devices Company, earnings per share came in at 0.53, beating analysts’ expectations of 0.49 by 0.04. This compares to $0.10 EPS in the same period last year. The net profit margin was 12.00% and return on equity was 8.64% for BSX. The company reported revenue of $3.73 billion for the quarter, compared to $3.24 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 14.9 percent. For the current quarter, analysts expect BSX to generate $4.01B in revenue.
